Quick Takeaways Why It Matters? AgmaVet For Horses gives vets and owners a non-NSAID, nutraceutical option for managing lameness and mobility, which may appeal where long-term drug side effects are a concern. By targeting both nerve function and joint healt...
Quick Takeaways: Why It Matters? The recall may temporarily weaken confidence in Neogen’s veterinary portfolio and open space for rival hyaluronate or wound-care products. It also underscores regulatory and safety scrutiny around off-label use, likely prompting v...
Quick Takeaways: Why It Matters? Full approval and label expansion make Vetmedin the standard of care for early-stage MMVD, locking in pimobendan as the only FDA‑approved option for delaying CHF in Stage B2 dogs and driving guideline‑aligned, earli...
Quick Takeaways: Why It Matters? The deal adds another science‑forward brand to epiq’s portfolio and deepens its role as a specialty distributor that can take microbiome‑based innovations from H&H/Zesty Paws into the vet channel with supply-chain and market‑access...
Quick Takeaways: Why It Matters? By adding a feline‑specific soft chew built on proprietary CBD + CBDA data, ElleVet deepens its position as a science‑led cannabinoid brand and expands use beyond dogs into a harder‑to‑treat cat population. The palatable, lo...
Quick Takeaways: Why It Matters? By unifying PIMS, AI scribing, and decision support (Plumb’s, Standards of Care, etc.) in one intelligence-native stack, Instinct is positioning itself as a full operating platform for modern hospitals, which could pressure legacy PIMS vendors t...
Quick Takeaways: Why It Matters? By expanding Cancer Dx and inVue Dx, IDEXX tightens its grip on veterinary oncology workflows, nudging clinics toward proactive, panel-based cancer screening rather than reactive testing. Bundling mast cell detection at no extra c...
Quick Takeaways: Why It Matters? The DR50 Plus strengthens IDEXX’s imaging ecosystem, giving clinics a premium option that combines lower dose with sharper, AI-optimized images. Dose reduction and fewer retakes can improve staff and patient safety, while tighter ...
Quick Takeaways: Why It Matters? The Bioguard agreement deepens KVP SafePath’s diagnostics pipeline with access to a broad reagent/IP library and a faster path to USDA‑licensed 4DX/3DX panels, positioning the company to enter a >$500 million North America...
Quick Takeaways: Why It Matters? With both TAS and RXE accepted, Loyal moves significantly closer to commercializing the first true longevity drug in veterinary medicine, turning canine lifespan extension into a near-term, rather than speculative, market. If LOY-002 reache...